OBI’s BOD resolved to in-license a preclinical project from a biotech company specialized in novel cancer therapies

1.Date of occurrence of the event: 2021/11/26 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4.Reciprocal shareholding ratios: No applicable 5.Cause of occurrence: The Company’s Board of Directors resolved to in-license a preclinical discovery project from a biotechnology company specialized in novel cancer therapeutics. The licensing […]